In the July 2017 issue, in the article “Faster, deeper, smaller—the rise of antibody-like scaffolds,” it was incorrectly stated that Janssen's fynomer drug for psoriasis was discontinued “when it induced rheumatoid arthritis”; in fact, it was discontinued “after it induced transient rashes and muscle pain.” In addition, it was stated that affibodies were invented by “a group led by Fredrik Frejd,” instead of “researchers at the Royal Institute of Technology, Stockholm, and Fredrik Frejd.” The errors were corrected in the HTML and PDF versions of the article on 9 August and 13 April 2018, respectively.
In the June 2017 issue, in Table 1 of the article “First deuterated drug approved,” the drug BMS-986165 was listed as a “deuterium-modified” version of rosuvastatin, rather than a “deuterium-modified” new molecular entity. The error was corrected in the html and pdf versions of the article on 13 April 2018.
Change history
13 April 2018
In the version of this correction notice initially published, the correction described in the first paragraph, second sentence, had not been made, nor had the correction in the second paragraph. Both corrections have been made as of 13 April 2018. The error has been corrected in the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nbt0717-602
The online version of the original article can be found at 10.1038/nbt0617-493
Rights and permissions
About this article
Cite this article
Corrections. Nat Biotechnol 35, 1004 (2017). https://doi.org/10.1038/nbt1117-1004c
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1117-1004c
